Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Recent clinical studies have demonstrated that a single subpsychotomimetic dose of ketamine, an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, produces a rapid antidepressant response in patients with major depressive disorder, with effects lasting up to 2 weeks. Despite enthusiasm about this unexpected efficacy of ketamine, its widespread use as a fast-acting antidepressant in routine clinical settings is curtailed by its abuse potential as well as possible psychotomimetic effects. However, the ability of ketamine to produce a rapid and long-lasting antidepressant response in patients with depression provides a unique opportunity for investigation of mechanisms that mediate these clinically relevant behavioral effects. From a mechanistic perspective, it is easy to imagine how activation of NMDA receptors may trigger cellular and behavioral responses; it is relatively more difficult, however, to envision how transient blockade of one of the key pathways for neuronal communication produces a persistent beneficial effect. The authors discuss recent work linking ketamine's mechanism of action to homeostatic synaptic plasticity processes activated after suppression of NMDA-mediated glutamatergic neurotransmission. They focus on their recent work demonstrating that ketamine-mediated blockade of NMDA receptors at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase, resulting in reduced eEF2 phosphorylation and desuppression of rapid dendritic pr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Homeostatic plasticity in the developing nervous system
Turrigiano, G. G., & Nelson, S. B. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1327 · Cited by 2,485
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 2
- Schwartz PH, 1991, Res Commun Chem Pathol Pharmacol, 73, 181
- Gómez-Galán M, Mol Psychiatry
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
“It is interesting that a recent study of patients with major depressive disorder found that carriers of the Val66Met (rs6265) single nucleotide polymorphism—representing an attenuation of BDNF functioning—had a smaller antidepressant response to ketamine (36), in line with findings in animal models (34, 37, 38).”
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
BDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2022) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 607
Self-citationThe mechanisms and functions of spontaneous neurotransmitter release
Kavalali, E. T. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3875 · Cited by 486
Self-citationLucassen, P. J., Pruessner, J., Sousa, N., Almeida, O. F. X., Van Dam, A. M., Rajkowska, G., Swaab, D. F., & Czéh, B. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1223-5 · Cited by 441
“mine [95, 244] are considered promising targeta for new”
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
“…would suggest that interventions which directly (e.g., ketamine and riluzole) or indirectly (e.g., scopolamine) modulate glutamate function may mitigate depressive symptoms in individuals with MDD (Khajavi et al., 2012; Salvadore and Singh, 2013; Carlson et al., 2013; Kavalali and Monteggia, 2012).”
BackgroundTreatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Cognitive impairment in depression: recent advances and novel treatments
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384
“Evidence has emerged in recent years that the underlying cause of depression lies in dysfunctions not only of the known aminergic neurotransmitter systems, but also of other circuits, such as the glutamatergic ones; similarly, the role of other pathogenetic mechanisms, such as loss of synaptic plasticity in areas invo…”
BackgroundEsketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
“Kavalali and Monteggia have also proposed that NMDA receptor antagonism deactivates eukaryotic elongation factor 2 (eEF2) kinase, leading to reduced eEF2 phosphorylation and increased translation of brain-derived neurotrophic factor (BDNF) (Kavalali and Monteggia, 2012).”
BackgroundAntidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
“It has been suggested that this increased sensitivity or “synaptic scaling” is necessary to maintain stability in synaptic plasticity and increased protein synthesis in the presence of chronic NMDAR blockade (Kavalali and Monteggia, 2012).”
BackgroundAcute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
“Extracellular field potential recordings Hippocampal slices (400 m) were prepared from 20 – 60-d-old animals (Sprague Dawley rats, eEF2K and BDNF knock-out mice were used as indicated).”
MethodSelf-citationNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
“, 2016), ketamine’s effects on NMDARs appear to contribute significantly to anesthetic, analgesic, and psychotomimetic, if not also antidepressant, actions (Kavalali and Monteggia, 2012; Abdallah et al., 2015).”
BackgroundKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
Goodwill, H. L., Manzano-Nieves, G., Gallo, M., Lee, H.-I., Oyerinde, E., Serre, T., & Bath, K. G. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0195-5 · Cited by 234
“Using this system, we find that ketamine has fast-acting antidepressant effects in ELS-exposed females; reversing home cage depressive-like behaviors, mirroring the rapid alleviation of core major depression symptoms following an intravenous dose of ketamine in otherwise treatment-resistant patients [68, 69].”
BackgroundGideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
“In this study, we found that memantine does not inhibit the phosphorylation of eEF2 or augment subsequent expression of BDNF, which are necessary requirements for ketamine-mediated antidepressant efficacy (8, 9, 13).”
BackgroundResultSelf-citationShiroma, P. R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C. S., & Lim, K. O. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 221
Franceschelli, A., Sens, J., Herchick, S., Thelen, C., & Pitychoutis, P. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.008 · Cited by 198
“Interestingly, our data in male mice are in agreement with Kavalali and Monteggia (2012) who suggested that ketamine-induced decrease in hippocampal glutamatergic activity may underlie the rapid antidepressant actions of ketamine.”
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder
Bunney, B. G., Li, J. Z., Walsh, D. M., Stein, R., Vawter, M. P., Cartagena, P., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Watson, S. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.138 · Cited by 180
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders
Kavalali, E. T., & Monteggia, L. M. (2020) · Neuron · doi:10.1016/j.neuron.2020.05.015 · Cited by 179
“Multiple studies from our group as well as others have demonstrated that ketamine administration elicits a unique form of synaptic plasticity that shares several attributes and molecular mechanisms that were previously identified in homeostatic synaptic scaling (Kavalali and Monteggia, 2012; Kavalali and Monteggia, 20…”
BackgroundSelf-citationGlutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 155
“…that sets in motion a cascade leading to downstream alterations in second messenger cascades leading to some of the cellular and molecular alterations observed in preclinical models, e.g., long-term potentiation (LTP)-like synaptogenesis (Duman and Aghajanian 2012; Kavalali and Monteggia 2012).”
Ketamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
De Berardis, D., Fornaro, M., Valchera, A., Cavuto, M., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102888 · Cited by 174
“The release of BDNF promotes a lot of synaptic plasticity mechanisms and dendritic spine modifications that have been proposed to underlie the long-term effects of ketamine administration [95], as well as of other antidepressants [96].”
BackgroundArosio, B., Guerini, F. R., Voshaar, R. C. O., & Aprahamian, I. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.626906 · Cited by 145
“Interestingly, the BDNF levels increased after an average time of 4 h after a low-dose infusion of ketamine, completely different from the evidence with other antidepressants, which require a more prolonged time (Autry et al., 2011; Kavalali and Monteggia, 2012; Haile et al., 2014).”
BackgroundRay, M. T., Shannon Weickert, C., & Webster, M. J. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.26 · Cited by 161
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
“These findings suggest that ketamine directly influences pyramidal neurons in the CA1 of the HPC, however, it is important to consider the region-specific neurocircuitry underlying these responses [98].”
Emerging links between homeostatic synaptic plasticity and neurological disease
Wondolowski, J., & Dickman, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00223 · Cited by 132
“…receptors lead to RA and BDNF synthesis in the postsynaptic cell and subsequent alteration of synaptic protein synthesis and retrograde signaling that homeostatically modulate presynaptic function (Jakawich et al., 2010; Chen et al., 2012; Henry et al., 2012; Kavalali and Monteggia, 2012).”
Background( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Rett Syndrome: Crossing the Threshold to Clinical Translation
Katz, D. M., Bird, A., Coenraads, M., Gray, S. J., Menon, D. U., Philpot, B. D., & Tarquinio, D. C. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2015.12.008 · Cited by 150
“Moreover, in addition to its acute effects on circuit function, work in other disease models has shown that ketamine also rapidly stimulates dendritic growth, BDNF translation, and expression of key synaptic proteins [67, 68], at least in part through activation of mTOR signaling, which is deficient in Mecp2 mutants […”
BackgroundAntidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
“In this regard it will be critical to fully delineate the specific synaptic mechanisms underlying ketamine action as this information will likely uncover additional synaptic proteins that can be targeted to elicit a rapid antidepressant response [42].”
BackgroundSelf-citationMechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
“These studies show that plasticity-related pathways, especially the BDNF signaling pathway, are influenced by ketamine treatment (Duman and Voleti, 2012; Kavalali and Monteggia, 2012; Reus et al., 2014; Yang et al., 2014; Zhou et al., 2014).”
BackgroundKetamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J. D., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022) · Journal of Pain Research · doi:10.2147/jpr.s360733 · Cited by 151
“4% of the US adult population.(4) Despite intense research efforts, the field has had little”
BackgroundInfluentialRoles of Presynaptic NMDA Receptors in Neurotransmission and Plasticity
Banerjee, A., Larsen, R. S., Philpot, B. D., & Paulsen, O. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2015.11.001 · Cited by 131
How could stress lead to major depressive disorder?
Richter-Levin, G., & Xu, L. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.04.001 · Cited by 120
Recent insights into the mode of action of memantine and ketamine
Johnson, J. W., Glasgow, N. G., & Povysheva, N. V. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.006 · Cited by 116
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Hanson, J. E., Yuan, H., Perszyk, R. E., Banke, T. G., Xing, H., Tsai, M.-C., Menniti, F. S., & Traynelis, S. F. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01614-3 · Cited by 113
Bal, M., Leitz, J., Reese, A. L., Ramirez, D. M. O., Durakoglugil, M., Herz, J., Monteggia, L. M., & Kavalali, E. T. (2013) · Neuron · doi:10.1016/j.neuron.2013.08.024 · Cited by 131
Self-citationFischell, J., Van Dyke, A. M., Kvarta, M. D., LeGates, T. A., & Thompson, S. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.112 · Cited by 122
Orozco-Solis, R., Montellier, E., Aguilar-Arnal, L., Sato, S., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.1176 · Cited by 119
“Gsk3β, a potent inhibitor of mammalian target of rapamycin complex 1 and a circadianrelevant gene, potentiates KT’s antidepressant effects in mice (57,58) and is thought to contribute to KT’s sustained actions beyond its relatively short half-life (2–3 hours) (59,60).”
How does ketamine elicit a rapid antidepressant response?
Kavalali, E. T., & Monteggia, L. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.005 · Cited by 111
Self-citationAleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.007 · Cited by 114
Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., & Pariante, C. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.87 · Cited by 108
Miniature Neurotransmission Regulates Drosophila Synaptic Structural Maturation
Choi, B. J., Imlach, W. L., Jiao, W., Wolfram, V., Wu, Y., Grbic, M., Cela, C., Baines, R. A., Nitabach, M. N., & McCabe, B. D. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.012 · Cited by 97
“First, a number of synaptic vesicle fusion molecules, such as vSNAREs, that are necessary for evoked NT are not essential for miniature NT and vice versa (Kavalali and Monteggia, 2012).”
Existing and Novel Biological Therapeutics in Suicide Prevention
Griffiths, J. J., Zarate, C. A., & Rasimas, J. J. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.06.012 · Cited by 93
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Tornese, P., Sala, N., Bonini, D., Bonifacino, T., La Via, L., Milanese, M., Treccani, G., Seguini, M., Ieraci, A., Mingardi, J., et al. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100160 · Cited by 101
“Importantly, the behavioral effects of KET have been suggested to be related to rapid activation of neurotrophic signaling and synaptic translation of Brain-Derived Neurotrophic Factor (BDNF) (Kavalali and Monteggia, 2015, 2012; Monteggia and Kavalali, 2013).”
BackgroundPatrizi, A., Picard, N., Simon, A. J., Gunner, G., Centofante, E., Andrews, N. A., & Fagiolini, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.018 · Cited by 100
“Influencing each of these targets leads to an upregulation of protein synthesis including BDNF (64,65), which then contributes to strengthened synaptic plasticity (66).”
A Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
“…work, we have shown ketamine, a non-competitive glutamate N-methyl-D-aspartate (NMDA) receptor antagonist that blocks open NMDA receptor channels (Kavalali and Monteggia, 2012) rather surprisingly induces a distinctive form of synaptic plasticity in the hippocampus (Autry et al., 2011; Gideons…”
Self-citationKotkowska, Z., & Strzelecki, D. (2022) · Pharmaceuticals · doi:10.3390/ph15040391 · Cited by 98
“Studies on rapid-acting antidepressant—ketamine—having different mechanisms of action than SSRIs and TCAs, showed that the rapid antidepressant response after its administration is mediated by an increase in BDNF levels [96].”
BackgroundPeriodic and aperiodic changes to cortical EEG in response to pharmacological manipulation
Salvatore, S. V., Lambert, P. M., Benz, A. M., Rensing, N. R., Wong, M., Zorumski, C. F., & Mennerick, S. J. (2024) · Journal of Neurophysiology · doi:10.1152/jn.00445.2023 · Cited by 97
Bonnet, U. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1072653 · Cited by 90
“…Duman et al. 2012; Marty and Spigelman 2012); 3) Increased neurotrophin (BDNF, NGF) levels after acute administration (Logrip, Janak, and Ron 2009; Kavalali and Monteggia 2012) and decreased neurotrophin levels during prolonged intake (Ke et al. 2014; Zhou et al. 2014); 4) Inhibition of…”
Backgrounddu Jardin, K. G., Liebenberg, N., Müller, H. K., Elfving, B., Sánchez, C., & Wegener, G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4327-5 · Cited by 93
“The two most widely held hypotheses both suggest that ketamine induces changes in glutamatergic neurotransmission in cortical areas, which results in brain derived neurotrophic factor (BDNF) release (Kavalali and Monteggia 2012, 2015; Dwyer and Duman 2013; Duman 2014).”
Strasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., et al. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12497 · Cited by 84
Anaesthesia for electroconvulsive therapy – new tricks for old drugs: a systematic review
Stripp, T. A., Jørgensen, M. B., & Olsen, N. V. (2017) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.12 · Cited by 87
Réus, G. Z., Carlessi, A. S., Titus, S. E., Abelaira, H. M., Ignácio, Z. M., da Luz, J. R., Matias, B. I., Bruchchen, L., Florentino, D., Vieira, A., et al. (2015) · Developmental Neurobiology · doi:10.1002/dneu.22283 · Cited by 81
“Ketamine-mediated blockade of NMDA receptors at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase, resulting in reduced eEF2 phosphorylation and suppression of rapid dendritic protein translation, including BDNF, which then contributes to synaptic plasticity mechanisms that mediate long term effects of the…”
BackgroundKetamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions
Salvadore, G., & Singh, J. B. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12103 · Cited by 81
“Converging lines of evidence suggests that major depression is associated with abnormalities in glutamatergic synaptic transmission [3] resulting in loss of synaptic plasticity in mood and emotion circuits [4,5].”
BackgroundPresynaptic origins of distinct modes of neurotransmitter release
Chanaday, N. L., & Kavalali, E. T. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2018.03.005 · Cited by 76
Self-citationRawat, R., Tunc‐Ozcan, E., McGuire, T. L., Peng, C., & Kessler, J. A. (2022) · Nature Communications · doi:10.1038/s41467-022-30386-5 · Cited by 81
Adaikkan, C., Taha, E., Barrera, I., David, O., & Rosenblum, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.028 · Cited by 76
Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice
Thelen, C., Sens, J. P., Mauch, J., Pandit, R., & Pitychoutis, P. M. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.041 · Cited by 80
Joffe, M. E., Santiago, C. I., Oliver, K. H., Maksymetz, J., Harris, N. A., Engers, J. L., Lindsley, C. W., Winder, D. G., & Conn, P. J. (2020) · Neuron · doi:10.1016/j.neuron.2019.09.044 · Cited by 76
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“Subsequent mechanistic research has shown that ketamine initiates a cascade of events that result in synaptic plasticity [31].”
BackgroundMonteggia, L. M., Malenka, R. C., & Deisseroth, K. A. (2014) · Nature · doi:10.1038/515200a · Cited by 77
Self-citationKetamine, Sleep, and Depression: Current Status and New Questions
Duncan, W. C., & Zarate, C. A. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0394-z · Cited by 76
Luoni, A., Macchi, F., Papp, M., Molteni, R., & Riva, M. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu061 · Cited by 70
“It has been recently postulated that synaptic mechanisms may be crucial mediators of the dysfunctions associated with mood disorders (Radley et al., 2006; Duman and Aghajanian, 2012; Kavalali and Monteggia, 2012).”
BackgroundEl Iskandrani, K. S., Oosterhof, C. A., El Mansari, M., & Blier, P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573809 · Cited by 75
“…involved in major depression (see Drevets et al. 2008) and in light of studies showing neuronal plasticity following ketamine administration (see Kavalali and Monteggia, 2012), the hippocampus was selected to assess whether the responsiveness of CA3 pyramidal neurons to ketamine could as well…”
BackgroundA unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
“…activation of AMPA receptors is associated with the increase in BDNF and mTOR signalling causes an increase in neuroplasticity-related gene expression and protein synthesis (Aleksandrova and Phillips, 2021; Kavalali and Monteggia, 2012; Kim et al., 2021; Li et al., 2010; Nosyreva et al., 2014).”
BackgroundDossat, A. M., Wright, K. N., Strong, C. E., & Kabbaj, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.022 · Cited by 72
“Previous reports posited that ketamine's up-regulation of AMPA receptor expression may underlie enhanced glutamatergic sensitivity and synaptic plasticity (Kavalali and Monteggia, 2012; Li et al., 2010).”
BackgroundMorrison, R. L., Fedgchin, M., Singh, J., Van Gerven, J., Zuiker, R., Lim, K. S., van der Ark, P., Wajs, E., Xi, L., Zannikos, P., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4828-5 · Cited by 72
“…showing improved performance at 10 h postdose merits further investigation, particularly in light of preclinical evidence in rodents that a single administration of ketamine alters synaptic plasticity in the hippocampus and medial prefrontal cortex (Kavalali and Monteggia 2012; Duman et al. 2016).”
BackgroundGlutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization
Khoodoruth, M. A. S., Estudillo‐Guerra, M. A., Pacheco‐Barrios, K., Nyundo, A., Chapa-Koloffon, G., & Ouanes, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.886918 · Cited by 73
“When evidence emerged about its rapid (within several hours) antidepressant effects (23), ketamine revolutionized the landscape as there was desperate need for urgent relief of suicidal crises and faster restoration of functioning, thereby providing a respite on economic and social burdens of treatment-resistant depre…”
BackgroundPerspectives on Zebrafish Models of Hallucinogenic Drugs and Related Psychotropic Compounds
Neelkantan, N., Mikhaylova, A., Stewart, A., Arnold, R., Gjeloshi, V., Kondaveeti, D., Poudel, M. K., & Kalueff, A. V. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400090q · Cited by 69
Cognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68
“…evidence suggests that depression is also associated with alterations in other neurotransmitter systems (such as glutamatergic transmission), as well as to a loss of synaptic plasticity in circuits involved in regulating mood and emotions (Sanacora et al., 2008; Kavalali and Monteggia, 2012).”
BackgroundAntidepressant mechanism of ketamine: perspective from preclinical studies
Scheuing, L., Chiu, C.-T., Liao, H.-M., & Chuang, D.-M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00249 · Cited by 65
“BDNF upregulation due to ketamine administration also leads to acute changes in synaptic plasticity (increased surface expression of AMPA receptors) within the hippocampus (Nosyreva et al., 2013; see Kavalali and Monteggia, 2012 for details about ketamine and synaptic plasticity).”
BackgroundHomer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress
Wagner, K. V., Hartmann, J., Labermaier, C., Häusl, A. S., Zhao, G., Harbich, D., Schmid, B., Wang, X.-D., Santarelli, S., Kohl, C., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.308 · Cited by 67
“Given the increasing body of evidence showing that NMDA receptor targeting agents produce rapid-acting antidepressant effects (Krystal et al, 2013; Kavalali and Monteggia, 2012), a Homer1a-mediated overactivation of this signaling pathway may profoundly affect antidepressant treatment efficacy.”
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
“Prior studies indicate that ketamine may act by modulating spontaneous synaptic transmission (Autry et al., 2011; Kavalali and Monteggia, 2012; Nosyreva et al., 2013).”
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
“…to the antidepressant-like effect of ketamine (Beurel et al., 2011) Desuppression of BDNF release mediated by blockade of NMDA receptors at rest (Kavalali and Monteggia, 2015, 2012) Spontaneous glutamate release and subsequent activation of NMDA receptors activate eEF2 kinase leading to…”
An Ethical Exploration of Barriers to Research on Controlled Drugs
Andreae, M. H., Rhodes, E., Bourgoise, T., Carter, G. M., White, R. S., Indyk, D., Sacks, H. S., & Rhodes, R. (2016) · The American Journal of Bioethics · doi:10.1080/15265161.2016.1145282 · Cited by 64
Off-label uses of drugs for depression
Skånland, S. S., & Cieślar‐Pobuda, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172732 · Cited by 63
Forkhead box O transcription factors as possible mediators in the development of major depression
Wang, H., Quirion, R., Little, P. J., Cheng, Y., Feng, Z., Sun, H., Xu, J., & Zheng, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.020 · Cited by 61
“These subcellular events include synaptic transmission, gene expression, neuronal morphological changes and many other molecular events in the brain (Kavalali and Monteggia, 2012; Pilar-Cuéllar et al., 2012; Seo et al., 2014).”
Towards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60
“…the underlying neurobiology of the antidepressant action of ketamine are rapidly emerging (Autry et al. 2011; Beurel et al. 2011; O'Connor et al. 2011; Duman et al. 2012; Inta et al. 2009; Kavalali and Monteggia 2012; Kos et al. 2006; Li et al. 2010; Lindholm et al. 2012; Zarate et al. 2013).”
BackgroundBridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Self-citationChen, M.-H., Lin, W.-C., Wu, H.-J., Cheng, C.-M., Li, C.-T., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., & Su, T.-P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.075 · Cited by 57
Miniature neurotransmission is required to maintain Drosophila synaptic structures during ageing
Banerjee, S., Vernon, S. W., Jiao, W., Choi, B. J., Ruchti, E., Asadzadeh, J., Burri, O., Stowers, R. S., & McCabe, B. D. (2021) · Nature Communications · doi:10.1038/s41467-021-24490-1 · Cited by 57
Lilius, T. O., Jokinen, V., Neuvonen, M., Niemi, M., Kalso, E. A., & Rauhala, P. V. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12974 · Cited by 56
“Its main clinical use is as an anaesthetic agent, but it is increasingly studied for the treatment of chronic pain and also depression (Kavalali and Monteggia, 2012).”
BackgroundHCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54
The role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52
Self-citationTherapeutic potential of ketamine for alcohol use disorder
Worrell, S. D., & Gould, T. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.006 · Cited by 52
Elucidating the Possible Role of FoxO in Depression
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03364-4 · Cited by 52
Antidepressant-like effects of a novel curcumin derivative J147: Involvement of 5-HT1A receptor
Lian, L., Xu, Y., Zhang, J., Yu, Y., Zhu, N., Guan, X., Huang, H., Chen, R., Chen, J., Shi, G., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.003 · Cited by 51
“It is well known that ketamine is rapidly acting and longlasting antidepressant in patients suffering from major depressive disorder (Autry et al., 2011; Kavalali and Monteggia, 2012; Price et al., 2009).”
Schott, B. H., Assmann, A., Schmierer, P., Soch, J., Erk, S., Garbusow, M., Mohnke, S., Pöhland, L., Romanczuk‐Seiferth, N., Barman, A., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.10 · Cited by 49
Petrov, A. M., Yakovleva, A. A., & Zefirov, A. L. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.279695 · Cited by 49
“Taken together, these factors could decrease the efficacy of synaptic transmission (Kavalali & Monteggia, 2012).”
BackgroundRecent advances in the study of anesthesia-and analgesia-related mechanisms of S-ketamine
Zhou, J., Peng, G., Liang, W., Chen, Z., Liu, Y., Wang, B., Guo, M., Deng, Y.-L., Jun-ming, Y., Zhong, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228895 · Cited by 46
“Modulation of Ca by S-ketamine binding to the GluN2B subunit in the ionotropic glutamate receptor NMDA may lead not only to sustained activation of AMPA receptors (Kavalali and Monteggia, 2012; Zhang et al., 2021) but also to activation of glutamateindependent pathways that induce Ca inflow as well as calcium pool mob…”
BackgroundLolak, S., Suwannarat, P., & Lipsky, R. H. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800977-2.00005-x · Cited by 46
Metadata
- Authors
- Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Venue
- American Journal of Psychiatry
- Published
- 2012-11
- Volume
- 169
- Issue
- 11
- Pages
- 1150-1156
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2124203952
- Cited by
- 258
- References
- 48
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 10 · 2023: 11 · 2022: 16 · 2021: 18 · 2020: 11 · 2019: 19 · 2018: 15 · 2017: 17 · 2016: 20 · 2015: 27 · 2014: 31 · 2013: 31 · 2012: 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 070727, R01MH066198, MH-066198, R01MH070727)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, major depressive disorder, NMDA receptor antagonism, homeostatic plasticity, eEF2K, eEF2 phosphorylation, brain-derived neurotrophic factor, glutamatergic neurotransmission, presynaptic neurotransmitter release, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Brain, Disease Models, Animal, Humans, Ketamine, Synaptic Transmission, Neuronal Plasticity, Synapses, Synaptic Vesicles, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Neurotransmitter Agents, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.